Edmund M. T. Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edmund M. T. Lau has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- David Stephen Celermajer
University of Sydney
11 shared publications - Marc Humbert
INSERM UMR_S 999, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Université Paris–Saclay , Le Kremlin Bicêtre
11 shared publications - David Montani
INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
7 shared publications - Olivier Sitbon
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
6 shared publications Anne Keogh
Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia.School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, Australia
5 shared publicationsCarolyn Corrigan
Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia.School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia
5 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 1-9
Prevalence and risk factors of obstructive sleep apnoea in people with sarcoidosis: a narrative review
Background: Emerging evidence suggests a link between sarcoidosis and obstructive sleep apnoea (OSA). Previous studies have reported a high prevalence of OSA in people with sarcoidosis; however, much of this evidence has been derived from retrospective analyses. Recently, prospective cohort studies have provided further insight into potential interactions between sarcoidosis and OSA. This narrative review aims to synthesise current evidence on the prevalence of OSA in people with sarcoidosis and identify associated risk factors. Methods: We conducted a search of Pubmed, Medline, the Cochrane Library and the Register of Controlled Trials and identified eight studies that evaluated the prevalence of OSA in people with sarcoidosis. Results: The prevalence of OSA in sarcoidosis patients ranged from 44% to 88%. Mild OSA was generally more common than moderate to severe OSA, with prevalence rates of 24% to 52% for mild cases and 5% to 51% for moderate to severe cases. Advancing age and elevated body mass index (BMI) were consistently associated with increased OSA risk. Corticosteroid therapy and sex showed mixed associations, while parenchymal lung involvement was not linked to increased OSA risk in any study. Conclusion: The prevalence of OSA in people with sarcoidosis is high. Conventional risk factors for OSA, including age and BMI, also apply in this group. Further prospective studies with larger, well-defined cohorts are warranted to clarify these associations and explore the potential bidirectional relationship between sarcoidosis and OSA. Studies should expand our knowledge on symptoms and hypoxic burden of subjects with sarcoidosis and OSA.
- 1 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 1-9
Open AccessPrevalence and risk factors of obstructive sleep apnoea in people with sarcoidosis: a narrative review
Background: Emerging evidence suggests a link between sarcoidosis and obstructive sleep apnoea (OSA). Previous studies have reported a high prevalence of OSA in people with sarcoidosis; however, much of this evidence has been derived from retrospective analyses. Recently, prospective cohort studies have provided further insight into potential interactions between sarcoidosis and OSA. This narrative review aims to synthesise current evidence on the prevalence of OSA in people with sarcoidosis and identify associated risk factors. Methods: We conducted a search of Pubmed, Medline, the Cochrane Library and the Register of Controlled Trials and identified eight studies that evaluated the prevalence of OSA in people with sarcoidosis. Results: The prevalence of OSA in sarcoidosis patients ranged from 44% to 88%. Mild OSA was generally more common than moderate to severe OSA, with prevalence rates of 24% to 52% for mild cases and 5% to 51% for moderate to severe cases. Advancing age and elevated body mass index (BMI) were consistently associated with increased OSA risk. Corticosteroid therapy and sex showed mixed associations, while parenchymal lung involvement was not linked to increased OSA risk in any study. Conclusion: The prevalence of OSA in people with sarcoidosis is high. Conventional risk factors for OSA, including age and BMI, also apply in this group. Further prospective studies with larger, well-defined cohorts are warranted to clarify these associations and explore the potential bidirectional relationship between sarcoidosis and OSA. Studies should expand our knowledge on symptoms and hypoxic burden of subjects with sarcoidosis and OSA.
- 15 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 260-261
Lung transplantation for chronic thromboembolic pulmonary hypertension (CTEPH): A treatment of last resort
- 15 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 260-261
Lung transplantation for chronic thromboembolic pulmonary hypertension (CTEPH): A treatment of last resort
- Open Access
- 23 October 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002496
Long-term mortality in patients with chronic obstructive pulmonary disease requiring acute non-invasive ventilation with and without obstructive sleep apnoea
Introduction: Chronic obstructive pulmonary disease (COPD)/obstructive sleep apnoea (OSA) overlap syndrome (OVS) is associated with higher mortality compared with COPD alone in stable outpatients. However, the prognosis of patients hospitalised with acute hypercapnic respiratory failure (ARF) is unclear. Methods: In this retrospective cohort study, 124 patients with COPD and 44 patients with OVS were treated with positive airway pressure (PAP) for ARF and followed up for a median of 20.6 months (IQR 3.80–53.4). Patients treated in the emergency or intensive care units and did not continue PAP on the wards were excluded. We compared patient characteristics and overall survival. Results: Mean (SD) age of participants was 71 (9.7) years and 51% were males. Patients with OVS had a higher prevalence of hypertension (75% vs 50.0%, p=0.004) and type 2 diabetes mellitus (45.5% vs 19.4%, p<0.001). There was no difference in arterial pH or carbon dioxide levels at presentation. On univariate analysis, mortality was lower in OVS compared with patients with COPD alone (HR 0.57, 95% CI 0.37 to 0.87). Median survival was 51.0 (95% CI 38.1 to 93.7) months in OVS and 27.7 (95% CI 16.9 to 35.1) months in COPD alone. Median survival in OVS prescribed home PAP therapy was significantly higher (59.0 months) compared with OVS not discharged on therapy (36.1 months), and to patients with COPD, irrespective of home therapy prescription (p=0.022). After adjusting for multiple known confounders, patients with OVS still appeared to have lower mortality; however, this was no longer statistically significant (HR 0.75, 95% CI 0.45 to 1.24). Discussion: We found that patients with COPD and ARF requiring non-invasive ventilation may have higher mortality rates compared with patients with OVS. Patients with OVS treated with home PAP had lower mortality compared with patients not prescribed PAP on discharge. These findings suggest that patients with COPD who present with ARF may benefit from early diagnosis of OSA and initiation of long-term PAP therapy.
- 23 October 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002496
Open AccessLong-term mortality in patients with chronic obstructive pulmonary disease requiring acute non-invasive ventilation with and without obstructive sleep apnoea
Introduction: Chronic obstructive pulmonary disease (COPD)/obstructive sleep apnoea (OSA) overlap syndrome (OVS) is associated with higher mortality compared with COPD alone in stable outpatients. However, the prognosis of patients hospitalised with acute hypercapnic respiratory failure (ARF) is unclear. Methods: In this retrospective cohort study, 124 patients with COPD and 44 patients with OVS were treated with positive airway pressure (PAP) for ARF and followed up for a median of 20.6 months (IQR 3.80–53.4). Patients treated in the emergency or intensive care units and did not continue PAP on the wards were excluded. We compared patient characteristics and overall survival. Results: Mean (SD) age of participants was 71 (9.7) years and 51% were males. Patients with OVS had a higher prevalence of hypertension (75% vs 50.0%, p=0.004) and type 2 diabetes mellitus (45.5% vs 19.4%, p<0.001). There was no difference in arterial pH or carbon dioxide levels at presentation. On univariate analysis, mortality was lower in OVS compared with patients with COPD alone (HR 0.57, 95% CI 0.37 to 0.87). Median survival was 51.0 (95% CI 38.1 to 93.7) months in OVS and 27.7 (95% CI 16.9 to 35.1) months in COPD alone. Median survival in OVS prescribed home PAP therapy was significantly higher (59.0 months) compared with OVS not discharged on therapy (36.1 months), and to patients with COPD, irrespective of home therapy prescription (p=0.022). After adjusting for multiple known confounders, patients with OVS still appeared to have lower mortality; however, this was no longer statistically significant (HR 0.75, 95% CI 0.45 to 1.24). Discussion: We found that patients with COPD and ARF requiring non-invasive ventilation may have higher mortality rates compared with patients with OVS. Patients with OVS treated with home PAP had lower mortality compared with patients not prescribed PAP on discharge. These findings suggest that patients with COPD who present with ARF may benefit from early diagnosis of OSA and initiation of long-term PAP therapy.
- 3 July 2024
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 77, 101972
Sleep-related disorders in patients with precapillary pulmonary hypertension
- 3 July 2024
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 77, 101972
Sleep-related disorders in patients with precapillary pulmonary hypertension
- Open Access
- 17 May 2022
- Published by Elsevier in JACC: Asia
- Vol. 2 (3) , 256-257
Inherited Thrombophilia in Chinese CTEPH Patients
- 17 May 2022
- Published by Elsevier in JACC: Asia
- Vol. 2 (3) , 256-257
Open AccessInherited Thrombophilia in Chinese CTEPH Patients
- Open Access
- 21 October 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (11) , 1326-1327
In Reply
- 21 October 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (11) , 1326-1327
Open AccessIn Reply
- 5 October 2021
- Published by Wiley in Respirology
- Vol. 26 (12) , 1171-1180
Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry
Background and objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%–4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically operable disease. The epidemiology and long‐term outcomes of CTEPH have not been previously described in Australia and New Zealand.Methods: Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry for patients diagnosed with CTEPH between January 2004 and March 2020. Baseline characteristics, treatment strategies, outcome data and long‐term survival are reported.Results: A total of 386 patients were included with 146 (37.8%) undergoing PEA and 240 (62.2%) in the non‐PEA group. PEA patients were younger (55 ± 16 vs. 62 ± 16 years, p < 0.001) with higher baseline 6‐min walk distance (6MWD; 405 ± 122 vs. 323 ± 146 m, p = 0.021), whilst both groups had similar baseline pulmonary haemodynamics. Pulmonary hypertension‐specific therapy was used in 54% of patients post‐PEA and 88% in the non‐PEA group. The 1‐, 3‐ and 5‐year survival rates were 93%, 87% and 84% for the PEA group compared to 86%, 73% and 62%, respectively, for the non‐PEA group (p < 0.001). Multivariate survival analysis showed baseline 6MWD was an independent predictor of survival in both operated and medically managed patients.Conclusion: In this first multicentre report of CTEPH in Australia and New Zealand, long‐term survival is comparable to that in other contemporary CTEPH registries. However, PEA was only performed in a minority of CTEPH patients (37.8%) and significantly less than overseas reports. Greater awareness of PEA and improved patient access to experienced CTEPH centres are important priorities.
- 5 October 2021
- Published by Wiley in Respirology
- Vol. 26 (12) , 1171-1180
Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry
Background and objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%–4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically operable disease. The epidemiology and long‐term outcomes of CTEPH have not been previously described in Australia and New Zealand.Methods: Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry for patients diagnosed with CTEPH between January 2004 and March 2020. Baseline characteristics, treatment strategies, outcome data and long‐term survival are reported.Results: A total of 386 patients were included with 146 (37.8%) undergoing PEA and 240 (62.2%) in the non‐PEA group. PEA patients were younger (55 ± 16 vs. 62 ± 16 years, p < 0.001) with higher baseline 6‐min walk distance (6MWD; 405 ± 122 vs. 323 ± 146 m, p = 0.021), whilst both groups had similar baseline pulmonary haemodynamics. Pulmonary hypertension‐specific therapy was used in 54% of patients post‐PEA and 88% in the non‐PEA group. The 1‐, 3‐ and 5‐year survival rates were 93%, 87% and 84% for the PEA group compared to 86%, 73% and 62%, respectively, for the non‐PEA group (p < 0.001). Multivariate survival analysis showed baseline 6MWD was an independent predictor of survival in both operated and medically managed patients.Conclusion: In this first multicentre report of CTEPH in Australia and New Zealand, long‐term survival is comparable to that in other contemporary CTEPH registries. However, PEA was only performed in a minority of CTEPH patients (37.8%) and significantly less than overseas reports. Greater awareness of PEA and improved patient access to experienced CTEPH centres are important priorities.
- 1 October 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 187, 106581
Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay
- 1 October 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 187, 106581
Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay